Search

Your search keyword '"Loriot Y"' showing total 1,014 results

Search Constraints

Start Over You searched for: Author "Loriot Y" Remove constraint Author: "Loriot Y"
1,014 results on '"Loriot Y"'

Search Results

3. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

5. Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial

6. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer

7. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

8. Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma

13. Recommandations du Comité de cancérologie de l’Association Française d’Urologie (CC-AFU) pour la bonne pratique des instillations intravésicales de mitomycine C, d’épirubicine et de BCG pour le traitement des tumeurs de la vessie n’infiltrant pas le muscle (TVNIM)

17. Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress)

19. Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

20. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

21. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

22. Safety and efficacy of antibody drug conjugates in older patients with solid tumors

23. P1.23-07 Clinical Impact of Clonal Hematopoiesis in Patients with Advanced Non-small Cell Lung Cancer: Results of the CHIC Study

24. Pemigatinib for Metastatic or Surgically Unresectable Urothelial Carcinoma With FGF/FGFR Genomic Alterations: Final Results From FIGHT-201

25. ANTIBODY DRUG CONJUGATES IN OLDER PATIENTS: STATE OF THE ART

26. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases

30. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study

31. 41P BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?

33. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment

36. Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

38. EE301 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) As First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma (La/mUC) in France

39. AVENANCE : efficacité et tolérance en vie réelle d'avelumab en traitement d'entretien de première ligne (1LM) chez les patients atteints d'un carcinome urothélial avancé (aUC) et analyse exploratoire des traitements...

42. Toxicités et complications chirurgicales du Pembrolizumab administré avant cystectomie chez les patients atteints de cancer de la vessie infiltrant le muscle : résultats de l’essai pandore

43. Trial In Progress: DISCUS: A randomized phase II study comparing 3 vs. 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer

44. 34P Gustave Roussy Match-R study: A descriptive analysis of the molecular target population

45. Detection of myeloid malignancies through cfDNA profiling in patients with advanced stage cancer

46. 129P Molecular screening and early phase trial inclusion for head and neck squamous cell carcinoma patients

47. High prevalence of Clonal Hematopoiesis of indeterminate potential (CHIP) associated mutations in elderly patients with solid tumors

48. 1405P Circulating tumor DNA in advanced prostate cancer: Focus on high blood tumor mutational burden (h-bTMB)

49. 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)

50. 1752P Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011

Catalog

Books, media, physical & digital resources